公司于近日收到公司实际控制人之一致行动人函告，获悉其所持有的 公司部分股份办理了质押业务，具体情况如下。 股东 名称 是否为控 股股东或 第一大股 东及其一 致行动人 本 次 质 押数量 占 其 所 持 股 份 比例 占公司 总股本 比例 是 否 为 限 售 股 （如是， 注 明 限 售类型） 是否为 补充质 押 质 押 起 始日 质 押 到 期日 质 权 人 质 押 用 途 刘妍 超 是 18,792 ,000 7.06% 4.50% 否 否 2025 年 11 月 7 日 至办理 解除质 押登记 手续之 日止 屹贲 有限 其他（投 资合作） 刘雯 超 是 18,792 ,000 7.06% 4.50% 否 否 2025 年 11 月 7 日 至办理 解除质 押登记 手续之 日止 屹贲 有限 其他（投 资合作） 刘思 超 是 18,185 ,231 6.83% 4.35% 否 否 2025 年 11 月 7 日 至办理 解除质 押登记 手续之 日止 屹贲 有限 其他（投 资合作） 一、本次股份质押基本情况 证券代码：301211 证券简称：亨迪药业 公告编号：2025-049 湖北亨迪药业股份有限公司 关于 ...

东方量化多策略混合A（006785）成立日期2019年2月22日，最新规模2878.44万。今年以来收益 32.45%，同类排名2692/8147；近一年收益24.18%，同类排名3043/8056；成立以来亏损2.63%。 东方量化多策略混合A（006785）基金经理为盛泽、王怀勋。 截至发稿，盛泽累计任职时间7年93天，现任基金资产总规模11.67亿元，任职期间最佳基金回报 132.76%， 任职期间最差基金回报-20.29%。 11月11日，亨迪药业涨5.08%，截至发稿，报16.34元/股，成交4.15亿元，换手率6.34%，总市值68.24亿 元。 资料显示，湖北亨迪药业股份有限公司位于湖北省荆门市掇刀区杨湾路122号，成立日期1995年12月29 日，上市日期2021年12月22日，公司主营业务涉及化学原料药及制剂产品的研发、生产和销售。主营业 务收入构成为：非甾体抗炎类68.06%，心血管类16.08%，其他8.86%，抗肿瘤类6.99%。 从基金十大重仓股角度 数据显示，东方基金旗下1只基金重仓亨迪药业。东方量化多策略混合A（006785）三季度持有股数1.16 万股，占基金净值比例为0.43 ...

Core Viewpoint - The flu sector has experienced a significant rally, with notable stock price increases among several pharmaceutical companies [1] Company Summaries - Special One Pharmaceutical has reached its daily limit increase in stock price [1] - Nanxin Pharmaceutical's stock has risen by over 6% [1] - Tailong Pharmaceutical, Hendi Pharmaceutical, and Zhongsheng Pharmaceutical have also seen stock price increases [1]

Core Viewpoint - The A-share market has seen a significant rise in flu-related stocks due to a noticeable increase in flu activity across China, with most provinces entering the flu epidemic period [1] Group 1: Stock Performance - Hendi Pharmaceutical has increased by over 14%, while Hualan Biological has risen by 11% [1] - Other notable performers include Peking University Pharmaceutical with a 10% increase, and Jinshi Yao with a rise of over 7% [1] - Several companies, including Teva Pharmaceutical, Erkang Pharmaceutical, and others, have also shown gains of over 5% [1] Group 2: Market Context - Recent data from the China CDC indicates that flu virus cases have surpassed other respiratory viruses, marking a significant shift in the current flu season [1] - Since mid-October, sales of related medications, such as Oseltamivir, have increased, with production running continuously [1]

Core Insights - Hendi Pharmaceutical experienced a 3.25% decline in stock price on November 6, with a trading volume of 217 million yuan [1] - The company reported a financing buy-in of 27.85 million yuan and a net financing buy of 5.98 million yuan on the same day [1] Financing Overview - As of November 6, the total financing and securities balance for Hendi Pharmaceutical was 158 million yuan, accounting for 2.70% of its market capitalization [1] - The current financing balance exceeds the 70th percentile of the past year, indicating a relatively high level [1] - No shares were sold or repaid in the securities lending market on November 6, with the securities lending balance at zero, which is below the 50th percentile of the past year [1] Company Performance - As of October 31, the number of shareholders for Hendi Pharmaceutical increased by 13.95% to 20,800, while the average circulating shares per person decreased by 12.24% to 20,040 shares [2] - For the period from January to September 2025, the company reported a revenue of 319 million yuan, a year-on-year decrease of 4.52%, and a net profit attributable to shareholders of 20.93 million yuan, down 71.96% year-on-year [2] - Since its A-share listing, Hendi Pharmaceutical has distributed a total of 378 million yuan in dividends, with 306 million yuan distributed over the past three years [2] Business Composition - Hendi Pharmaceutical's main business includes the research, production, and sales of chemical raw materials and formulations, with revenue composition as follows: non-steroidal anti-inflammatory drugs 68.06%, cardiovascular drugs 16.08%, others 8.86%, and anti-tumor drugs 6.99% [1]

（文章来源：证券日报） 证券日报网讯亨迪药业11月4日在互动平台回答投资者提问时表示，截至2025年10月31日，公司股东户 数为20838户。 ...

Core Viewpoint - Hendi Pharmaceutical, established in December 1995 and listed on the Shenzhen Stock Exchange in December 2021, is a significant player in the domestic chemical raw materials pharmaceutical sector, focusing on the R&D, production, and sales of chemical raw materials and formulations [1] Business Performance - For Q3 2025, Hendi Pharmaceutical reported revenue of 319 million yuan, ranking 38th among 47 companies in the industry, with the top company, Pro Pharmaceutical, achieving 7.764 billion yuan [2] - The net profit for the same period was 20.93 million yuan, placing the company 33rd in the industry, while the leading company, Zhejiang Pharmaceutical, reported 867 million yuan [2] Financial Ratios - As of Q3 2025, Hendi Pharmaceutical's debt-to-asset ratio was 5.92%, slightly up from 5.81% year-on-year, significantly lower than the industry average of 27.75%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 20.53%, down from 30.23% year-on-year, and below the industry average of 35.38%, suggesting a need for improvement in profitability [3] Executive Compensation - The chairman, Cheng Zhigang, received a salary of 668,300 yuan in 2024, an increase of 52,600 yuan from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 1.53% to 17,900, while the average number of circulating A-shares held per shareholder increased by 1.55% to 23,300 [5]

证券代码：301211 证券简称：亨迪药业 公告编号：2025-046 湖北亨迪药业股份有限公司 第二届董事会第十六次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 会议审议并通过了如下议案： 1、《2025 年第三季度报告》 经审议，董事会认为：公司《2025 年第三季度报告》的编制和审核程序符 合法律、行政法规和中国证券监督管理委员会、深圳证券交易所的规定，报告内 容真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈 述或重大遗漏。 具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）刊载的《2025 年第三季度报告》。 本议案已经公司董事会审计委员会审议通过。 表决结果：赞成 8 票，反对 0 票，弃权 0 票。该项议案获审议通过。 2、《关于补选第二届董事会战略委员会成员的议案》 一、董事会会议召开情况 湖北亨迪药业股份有限公司（以下简称"公司"）第二届董事会第十六次会 议于 2025 年 10 月 16 日以电话及邮件方式送达至全体董事，本次会议于 2025 年 10 月 27 日以现场和通讯方式召 ...

Financial Performance - The company's operating revenue for the third quarter was CNY 841.28 million, a decrease of 8.68% compared to the same period last year[5]. - Net profit attributable to shareholders was CNY 23.86 million, down 61.30% year-on-year[5]. - Basic earnings per share decreased by 60.00% to CNY 0.006 compared to the previous year[5]. - Net profit for the current period was CNY 20,933,355.19, down 72% from CNY 74,661,546.28 in the previous period[25]. - Earnings per share (EPS) for the current period was CNY 0.05, compared to CNY 0.18 in the previous period[25]. - The net profit for the first nine months of 2025 was significantly impacted by a 61.46% decrease in net cash flow from operating activities, totaling ¥18,870,338.04 compared to ¥48,958,629.78 in the same period of 2024[14]. Assets and Equity - Total assets as of September 30, 2025, were CNY 2,401,494,054.03, representing a decrease of 3.50% from the end of the previous year[10]. - The company's equity attributable to shareholders was CNY 2,259,307,721.16, down 2.18% from the end of the previous year[10]. - Total assets amounted to CNY 2,401,494,054.03, a slight decrease from CNY 2,488,655,694.01[22]. - Total equity attributable to shareholders was CNY 2,259,307,721.16, compared to CNY 2,309,688,533.16 in the previous period[22]. Cash Flow - The cash flow from operating activities was CNY 18.87 million, a decline of 61.46% compared to the same period last year[5]. - Operating cash inflow for the current period is CNY 313,930,607.85, a decrease from CNY 358,511,330.00 in the previous period, resulting in a net cash flow from operating activities of CNY 18,870,338.04, down from CNY 48,958,629.78[26]. - Cash inflow from investment activities totaled CNY 179,041,323.76, compared to CNY 88,261,830.31 in the previous period, with a net cash flow from investment activities of CNY 46,747,617.31, a significant improvement from a net outflow of CNY 1,085,211,025.10[26]. - Cash outflow from financing activities was CNY 72,815,730.94, down from CNY 138,240,000.00 in the previous period, leading to a net cash flow from financing activities of -CNY 72,815,730.94[27]. - The total cash and cash equivalents at the end of the period is CNY 535,821,483.35, slightly up from CNY 520,745,020.94 in the previous period[27]. Income and Expenses - Non-operating income for the period amounted to CNY 6,258,606.17, a decrease from CNY 20,389,536.01 in the previous year[8]. - The company reported a significant increase in prepayments, which rose by 61.54% to CNY 5,993,392.74 due to increased payments to suppliers[10]. - The company reported a financial expense of CNY -8,147,213.61, a significant improvement from CNY -44,105,422.65 in the previous period[24]. - The income tax expense decreased by 72.43%, amounting to ¥2,183,492.08, primarily due to a reduction in total profit[13]. - Total operating costs increased to CNY 318,613,218.65, up from CNY 263,843,342.98, reflecting a significant rise in operating expenses[24]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,918[16]. - The largest shareholder, Shanghai Yongda Sheng Business Consulting Co., Ltd., holds 38.25% of the shares, totaling 159,732,000 shares[16]. - The company issued 4.5 new shares for every 10 shares held, increasing the share capital to CNY 417.6 million, a 45.00% increase[12]. Other Information - The company did not report any other items that meet the definition of non-recurring gains and losses[9]. - The company has not yet adopted the new accounting standards effective from 2025[28]. - The third quarter financial report has not been audited[28].

Core Insights - Hendi Pharmaceutical reported that as of October 20, 2025, the number of shareholders is 18,287 [2] Company Summary - Hendi Pharmaceutical is actively engaging with investors through interactive platforms [2] - The company is tracking its shareholder base, indicating a focus on investor relations and transparency [2]